Immunome, Inc. IMNM
Regular-session close
After hours · Nov 19, 4:39 PM ET
- YTD
- -22.67%
- 1 year
- -6.11%
5D -1.15 (-6.13%)
- Market cap
- 1.96B
- EPS (ttm)
- -2.63
- Shares out
- 118.07M
- Forward P/E
- -6.41
- YTD return
- -22.67%
- 1-year return
- -6.11%
- 50-day average
- 20.09
- 200-day average
- 22.08
- Enterprise value
- 1.53B
- Price / book
- 4.16
- Volume
- 881.29K
- Avg volume
- 1.36M
- Open
- 16.80
- Previous close
- 16.78
- Day's range
- 16.45 – 17.18
- 52-week range
- 16.41 – 30.06
- Beta
- 2.66
- Analysts
- Strong Buy
- Price target
- 35.13 (+111.5%)
- Earnings date
- Mar 2, 2027
Key statistics
- Free cash flow
- -159.73M
- Total cash
- 461.58M
- Total debt
- 11.38M
- Return on equity
- -78.71%
- Short % of float
- 15.92%
Fundamental scorecard
4 of 25 checks passed on IMNM’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 23.00
- Target (mean)
- 35.13
- Target (high)
- 40.00
- Strong buy3
- Buy13
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 2, 2027
Expected Mar 2, 2027. Consensus EPS estimate -0.5996.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 2, 2027 | Dec 30, 2026 | -0.76 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | -0.62174 | -0.76 | -0.14 | -22.24% |
| Aug 11, 2026 | Jun 30, 2026 | -0.51381 | -0.65 | -0.14 | -26.51% |
| May 12, 2026 | Mar 31, 2026 | -0.60 | -0.48 | +0.12 | +20.00% |
| Mar 3, 2026 | Dec 31, 2025 | -0.59017 | -0.75 | -0.16 | -27.08% |
| Nov 6, 2025 | Sep 30, 2025 | -0.57 | -0.65 | -0.08 | -14.04% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | Stifel | main | Hold | Hold |
| Nov 10, 2026 | Piper Sandler | main | Overweight | Overweight |
| Oct 27, 2026 | Wedbush | reit | Outperform | Outperform |
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Oct 1, 2026 | Stifel | init | — | Hold |
| Sep 21, 2026 | Alliance Global Partners | init | — | Buy |
About Immunome, Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- immunome.com
News
Immunome to Present at Upcoming Investor Conferences
Immunome: De-Risked With The FDA, With An Admirably Deep Clinical Bench
Immunome Analysts Cut Their Forecasts After Q3 Results Stifel Maintains Hold on Immunome, Lowers Price Target to $23
Piper Sandler Maintains Overweight on Immunome, Lowers Price Target to $30
Immunome Says EMA Validates MAA For Varegacestat, Investigational, Oral, Once-Daily Gamma Secretase Inhibitor, For Treatment Of Adults With Desmoid Tumors
Wedbush Reiterates Outperform on Immunome, Maintains $35 Price Target
Immunome Showcases New Clinical Analyses Supporting Varegacestat's Profile In Desmoid Tumors At ESMO 2026
Your note
Sign in to keep a note on IMNM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARCHAS ISAAC | Director | Sale | Aug 11, 2026 | 0 |
| BIENAIME JEAN-JACQUES | Director | Purchase | Jun 4, 2026 | 43,415 |
| HIGGINS JACK | Officer | Conversion of Exercise of derivative security | Sep 10, 2026 | 59,250 |
| HORN KINNEY | Officer | Conversion of Exercise of derivative security | Aug 3, 2026 | 0 |
| LECHLEIDER ROBERT | Officer | Stock Award(Grant) | Jul 22, 2026 | 69,805 |
| ROSETT MAX | Chief Financial Officer | Stock Award(Grant) | Jul 22, 2026 | 101,287 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 17.12% | 20,211,392 | 335.71M | Sep 29, 2026 |
| FMR, LLC | 14.43% | 17,036,641 | 282.98M | Sep 29, 2026 |
| Blackrock Inc. | 7.56% | 8,929,024 | 148.31M | Sep 29, 2026 |
| Wellington Management Group, LLP | 5.12% | 6,041,333 | 100.35M | Sep 29, 2026 |
| Driehaus Capital Management, LLC | 4.22% | 4,976,950 | 82.67M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.13% | 4,882,131 | 81.09M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 6.08% | 7,179,563 | 119.25M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 4.24% | 5,004,684 | 83.13M | Sep 29, 2026 |
| T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 3.31% | 3,907,378 | 64.90M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 3.14% | 3,703,461 | 61.51M | Jul 30, 2026 |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 3.13% | 3,692,941 | 61.34M | Sep 29, 2026 |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Core Equity Trust | 2.87% | 3,392,151 | 56.34M | Jun 29, 2026 |
